AEterna Zentaris Inc. (AEZS) stock prices updated...
 

AEterna Zentaris Inc. stock price

AEterna Zentaris Inc. latest news:


  • 12/21/2017 06:23:12

    Aeterna Zentaris' stock soars toward 8-month high after Macrilen granted marketing approval

    Shares of AEterna Zentaris Inc. rocketed 66% in premarket trade, putting them on track to open at an eight-month high, after the biopharmaceutical company said Macrilen, used in the diagnosis of patients with adult growth hormone deficiency, was granted marketing approval by the Food and Drug Administration. The company plans to make Macrilen available commercially in the U.S. during the first quarter of 2018. "Clinical studies have demonstrated that growth hormone stimulation testing for AGHD with oral Macrilen (macimorelin) is reliable, well-tolerated, reproducible, safe and a much simpler test to conduct than currently available option," said Kevin Yuen, clinical investigator of the Barrow Neuroendocrinology Clinic. The stock had plunged 44% year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF had rallied 21% and the S&P 500 had climbed 20%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/20/2017 15:39:37

    Canada's Aeterna gets FDA approval for growth hormone deficiency test

    Dec 20 (Reuters) - Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency. The company said it intends to launch the test, Macrilen, in the United States during the first quarter of 2018.

  • 11/27/2017 15:34:28

    BRIEF-Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA

    Aeterna Zentaris Inc(AEZS): * AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY. * Aeterna Zentaris Inc (AEZS) - ‍MAA FOR USE OF MACRILEN FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY BEEN ACCEPTED BY EMA FOR REGULATORY REVIEW​ Source text for Eikon: Further company coverage:

  • More trends:

    Aethlon Medical, Inc.AEMD | Affimed N.V.AFMD | Affymetrix, Inc.AFFX | Agenus Inc.AGEN | Agile Therapeutics, Inc.AGRX | Agilysys, Inc.AGYS | Agios Pharmaceuticals, Inc.AGIO | AgroFresh Solutions, Inc.AGFS | AgroFresh Solutions, Inc.AGFSW | Aimmune Therapeutics, Inc.AIMT |